Scarica l'app Stockscreener
3.23
1.25%
0.04
Dopo l'orario di chiusura:
3.30
0.07
+2.17%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Anixa Biosciences Inc Borsa (ANIX) Ultime notizie
Millennium Management LLC Acquires Shares of 11,028 Anixa Biosciences, Inc. (NASDAQ:ANIX) - Defense World
Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the ESMO Gynaecological Cancers Congress 2025 - Kilgore News Herald
Everything You Need to Know About the New Breast Cancer Vaccine - Vogue
Bank of America Corp DE Sells 6,891 Shares of Anixa Biosciences, Inc. (NASDAQ:ANIX) - Defense World
3 Promising Penny Stocks With Market Caps Over $100M - simplywall.st
Anixa Biosciences’ (ANIX) Buy Rating Reaffirmed at D. Boral Capital - Defense World
What Makes ANIXA BIOSCIENCES INC (ANIX) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage - GuruFocus
Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage | ANIX Stock News - GuruFocus
Anixa Biosciences (ANIX) Maintains 'Buy' Rating with $10 Price T - GuruFocus
Anixa Biosciences (ANIX) Maintains 'Buy' Rating with $10 Price Target | ANIX Stock News - GuruFocus
Revolutionary Breast Cancer Prevention Vaccine Gets Major Media Spotlight: How It Could Eradicate Cancer - Stock Titan
Anixa Biosciences (ANIX) to Present at ESMO Gynaecological Cance - GuruFocus
Anixa Biosciences Announces Poster Presentation on Ovarian Cance - GuruFocus
Anixa Biosciences Announces Poster Presentation On Ovarian Cancer CAR-T Clinical Trial At ESMO Gynaecological Cancers Congress 2025 - MarketScreener
Breakthrough CAR-T Therapy for Ovarian Cancer: Anixa's Phase 1 Trial Results Coming at ESMO 2025 - Stock Titan
Jane Street Group LLC Purchases New Shares in Anixa Biosciences, Inc. (NASDAQ:ANIX) - Defense World
Anixa Biosciences (NASDAQ:ANIX) Upgraded by Wall Street Zen to Hold Rating - Defense World
All You Need to Know About Anixa Biosciences (ANIX) Rating Upgrade to Buy - MSN
Kalkine Lists top companies in the nasdaq Featuring Innovative Biotech Like Anixa Biosciences - Kalkine Media
FY2025 EPS Forecast for Anixa Biosciences Boosted by Analyst - Defense World
CEO Amit Kumar Increases Stake in Anixa Biosciences Inc with Rec - GuruFocus
Anixa Biosciences CEO Amit Kumar acquires $28,500 in stock - Investing.com Australia
Anixa Biosciences CEO Amit Kumar acquires $28,500 in stock By Investing.com - Investing.com Canada
Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year? - Yahoo Finance
H.C. Wainwright maintains Buy rating on Anixa Biosciences stock By Investing.com - Investing.com UK
Northern Trust Corp Trims Stock Position in Anixa Biosciences, Inc. (NASDAQ:ANIX) - Defense World
Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview - GuruFocus
Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview | ANIX Stock News - GuruFocus
Revolutionary Breast Cancer Prevention Vaccine Hits Major Milestone: Phase 1 Trial Fully Enrolled - Stock Titan
Anixa Biosciences (ANIX) Concludes Enrollment for Breast Cancer Vaccine Trial | ANIX Stock News - GuruFocus
Anixa Biosciences Announces Completion Of Enrollment In Phase 1 Trial Of Breast Cancer Vaccine - MarketScreener
Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine - GuruFocus
Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine | ANIX Stock News - GuruFocus
Revolutionary Breast Cancer Vaccine Achieves Major Milestone: 70% of Patients Show Promising Immune Response - Stock Titan
ANIXA BIOSCIENCES Earnings Preview: Recent $ANIX Insider Trading, Hedge Fund Activity, and More - Nasdaq
Anixa Biosciences to Present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10 - marketscreener.com
Anixa Biosciences’ (ANIX) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Anixa Biosciences (ANIX) Retains 'Buy' Rating with $10 Price Tar - GuruFocus
Anixa Biosciences (ANIX) Retains 'Buy' Rating with $10 Price Target | ANIX Stock News - GuruFocus
Anixa Biosciences Inc SEC 10-Q Report - TradingView
Anixa Biosciences (ANIX) Expected to Announce Earnings on Tuesday - Defense World
Anixa Biosciences CEO Provides Letter to Shareholders Outlining - GuruFocus
Anixa Biosciences CEO Provides Letter to Shareholders Outlining Significant Progress and Advancement Towards Potentially Transformative Milestones - Nasdaq
Breakthrough: Anixa's Cancer Vaccine Shows 70% Response Rate While CAR-T Therapy Extends Patient Survival - Stock Titan
Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting - Stock Titan
Renaissance Technologies LLC Has $34,000 Stock Holdings in Anixa Biosciences, Inc. (NASDAQ:ANIX) - Defense World
ANIXAnixa Biosciences Inc Latest Stock News & Market Updates - Stock Titan
Anixa Biosciences, Inc. (NASDAQ:ANIX) Shares Acquired by LPL Financial LLC - Defense World
0.68%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):